Lantern Pharma Announces Transaction to Evaluate BioNumerik’s Tavocept

Lantern Pharma has entered into an exclusive agreement to evaluate BioNumerik Pharmaceuticals’ Tavocept for human therapeutic indications using Lantern’s 5-M theranostic platform.

Tavocept is an investigational new drug candidate from BioNumerik’s portfolio that has shown potential for both oncology and non-oncology indications.

Lantern Pharma is a Precision Oncology Medicine company focused on using its proprietary 5-M platform to identify specific drug sensitivity signatures for patient tumor types.

The Tavocept transaction demonstrates Lantern’s commitment to the development of precision cancer drugs by employing its cutting-edge companion 5-M theranostics platform with the objective of providing more precise and therefore more effective treatments to patients sooner.

Arun Asaithambi of Lantern Pharma said: “We believe Lantern Pharma’s approach can be successfully applied to identify new value opportunities for drug candidates with promising potential that have encountered development challenges.

“We are excited about Tavocept and the potential to enhance its therapeutic potency through the application of our 5-M approach.”

BioNumerik Pharmaceuticals president Thomas Lyles said:“We believe Tavocept has important potential to be of benefit to patients, and we are excited to be working with Lantern Pharma to examine possible ways to realize and expand that potential.”